|
1
|
Koenig W: Haemostatic risk factors for
cardiovascular diseases. Eur Heart J. 19:C39–C43. 1998.
|
|
2
|
Bennett WM: Letter: renal vein thrombosis
in nephrotic syndrome. Ann Intern Med. 83:577–578. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang A, Wang Y, Wang G, Zhou Z, Xun Z and
Tan X: Mesangial IgA deposits indicate pathogenesis of
antiglomerular basement membrane disease. Mol Med Rep. 5:1212–1214.
2012.PubMed/NCBI
|
|
4
|
Chugh KS, Malik N, Uberoi HS, Gupta VK,
Aggarwal ML and Singhal PC: Renal vein thrombosis in nephrotic
syndrome - a prospective study and review. Postgrad Med J.
57:566–570. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu Y, Yin WL, Ba YF, Tian L, Gu ZQ, Zhang
MS and Zhong CN: Transforming growth factor-1 promotes
transcriptional activation of plasminogen activator inhibitor type
1 in carcinoma-associated fibroblasts. Mol Med Rep. 6:1001–1005.
2012.
|
|
6
|
Dawson SJ, Wiman B, Hamsten A, Green F,
Humphries S and Henney AM: The two allele sequences of a common
polymorphism in the promoter of the plasminogen activator
inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in
HepG2 cells. J Biol Chem. 268:10739–10745. 1993.PubMed/NCBI
|
|
7
|
Burzotta F, Di Castelnuovo A, Amore C,
D’Orazio A, Di Bitondo R and Donati MB: 4G/5G promoter PAI-1 gene
polymorphism is associated with plasmatic PAI-1 activity in
Italians: a model of gene-environment interaction. Thromb
Haemostasis. 79:354–358. 1998.PubMed/NCBI
|
|
8
|
Nagano K, Ishida J, Unno M, Matsukura T
and Fukamizu A: Apelin elevates blood pressure in ICR mice with
L-NAME-induced endothelial dysfunction. Mol Med Rep. 7:1371–1375.
2013.PubMed/NCBI
|
|
9
|
Diamanti-Kandarakis E, Palioniko G,
Alexandraki K, Bergiele A, Koutsouba T and Bartzis M: The
prevalence of 4G5G polymorphism of plasminogen activator
inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its
association with plasma PAI-1 levels. Eur J Endocrinol.
150:793–798. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsantes AE, Nikolopoulos GK, Bagos PG,
Rapti E, Mantzios G, Kapsimali V and Travlou A: Association between
the plasminogen activator inhibitor-1 4G/5G polymorphism and venous
thrombosis. A meta-analysis. Thromb Haemostasis. 97:907–913.
2007.PubMed/NCBI
|
|
11
|
Binder A, Endler G, Muller M, Mannhalter C
and Zenz W: 4G4G genotype of the plasminogen activator inhibitor-1
promoter polymorphism associates with disseminated intravascular
coagulation in children with systemic meningococcemia. J Thromb
Haemost. 5:2049–2054. 2007. View Article : Google Scholar
|
|
12
|
Hoekstra T, Geleijnse JM, Schouten EG and
Kluft C: Plasminogen activator inhibitor-type 1: its plasma
determinants and relation with cardiovascular risk. Thromb
Haemostasis. 91:861–872. 2004.PubMed/NCBI
|
|
13
|
Kanfer A: Coagulation factors in nephrotic
syndrome. Am J Nephrol. 10:63–68. 1990. View Article : Google Scholar
|
|
14
|
Rabelink TJ, Zwaginga JJ, Koomans HA and
Sixma JJ: Thrombosis and hemostasis in renal disease. Kidney Int.
46:287–296. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Deguchi F, Tomura S, Yoshiyama N and
Takeuchi J: Intraglomerular deposition of coagulation-fibrinolysis
factors and a platelet membrane antigen in various glomerular
diseases. Nephron. 51:377–383. 1989. View Article : Google Scholar
|
|
16
|
Sraer JD, Kanfer A, Rondeau E and Lacave
R: Glomerular hemostasis in normal and pathologic conditions. Adv
Nephrol Necker Hosp. 17:27–55. 1988.PubMed/NCBI
|
|
17
|
Thomson C, Forbes CD, Prentice CR and
Kennedy AC: Changes in blood coagulation and fibrinolysis in the
nephrotic syndrome. Q J Med. 43:399–407. 1974.PubMed/NCBI
|
|
18
|
Yoshida Y, Shiiki H, Iwano M, Uyama H,
Hamano K, Nishino T and Dohi K: Enhanced expression of plasminogen
activator inhibitor 1 in patients with nephrotic syndrome. Nephron.
88:24–29. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma Z, Jhun B, Jung SY and Oh CK: Binding
of upstream stimulatory factor 1 to the E-box regulates the 4G/5G
polymorphism-dependent plasminogen activator inhibitor 1 expression
in mast cells. J Allergy Clin Immun. 121:1006–1012. 2008.
View Article : Google Scholar
|
|
20
|
White LA, Bruzdzinski C, Kutz SM,
Gelehrter TD and Higgins PJ: Growth state-dependent binding of
USF-1 to a proximal promoter E box element in the rat plasminogen
activator inhibitor type 1 gene. Expe Cell Res. 260:127–135. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi L, Allen RR, Lu Q, Higgins CE, Garone
R, Staiano-Coico L and Higgins PJ: PAI-1 transcriptional regulation
during the G0→G1 transition in human epidermal keratinocytes. J
Cell Biochem. 99:495–507. 2006.
|
|
22
|
Bendall AJ and Molloy PL: Base preferences
for DNA binding by the bHLH-Zip protein USF: effects of
MgCl2 on specificity and comparison with binding of Myc
family members. Nucleic Acids Res. 22:2801–2810. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Krag S, Danielsen CC, Carmeliet P,
Nyengaard J and Wogensen L: Plasminogen activator inhibitor-1 gene
deficiency attenuates TGF-beta1-induced kidney disease. Kidney Int.
68:2651–2666. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang AY, Poon P, Lai FM, Yu L, Choi PC and
Lui SF: Plasminogen activator inhibitor-1 gene polymorphism 4G/4G
genotype and lupus nephritis in Chinese patients. Kidney Int.
59:1520–1528. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suzuki H, Sakuma Y, Kanesaki Y, Eiro M,
Asahi K, Sanada H, Watanabe K, Katoh T and Watanabe T: Close
relationship of plasminogen activator inhibitor-1 4G/5G
polymorphism and progression of IgA nephropathy. Clin Nephrol.
62:173–179. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
He D, Li J, Zhao J, Fei J and Zhang X:
C/EBP homologous protein induces mesangial cell apoptosis under
hyperglycemia. Mol Med Rep. 7:445–448. 2013.PubMed/NCBI
|
|
27
|
Izuhara Y, Yamaoka N, Kodama H, Dan T,
Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C and
Miyata T: A novel inhibitor of plasminogen activator inhibitor-1
provides antithrombotic benefits devoid of bleeding effect in
nonhuman primates. J Cerebr Blood F Met. 30:904–912. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dieval J, Nguyen G, Gross S, Delobel J and
Kruithof EK: A lifelong bleeding disorder associated with a
deficiency of plasminogen activator inhibitor type 1. Blood.
77:528–532. 1991.PubMed/NCBI
|
|
29
|
Fay WP, Parker AC, Condrey LR and Shapiro
AD: Human plasminogen activator inhibitor-1 (PAI-1) deficiency:
characterization of a large kindred with a null mutation in the
PAI-1 gene. Blood. 90:204–208. 1997.PubMed/NCBI
|
|
30
|
Fay WP, Shapiro AD, Shih JL, Schleef RR
and Ginsburg D: Brief report: complete deficiency of
plasminogen-activator inhibitor type 1 due to a frame-shift
mutation. N Eng J Med. 327:1729–1733. 1992. View Article : Google Scholar : PubMed/NCBI
|
